أعرض في EDS

197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859

التفاصيل البيبلوغرافية
العنوان: 197TiP A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
المؤلفون: Charles S. Fuchs, Y-J. Bang, Yelena Y. Janjigian, Pooja Bhagia, Kan Li, S. Qin, David Adelberg, E. Van Cutsem, J. Tabernero
المصدر: Annals of Oncology. 31:S1316-S1317
بيانات النشر: Elsevier BV, 2020.
سنة النشر: 2020
مصطلحات موضوعية: Chemotherapy, medicine.medical_specialty, business.industry, medicine.medical_treatment, HER2 negative, Hematology, Pembrolizumab, Gastroesophageal Junction, medicine.disease, Gastroenterology, Double blind, First line therapy, Oncology, Internal medicine, Medicine, Adenocarcinoma, In patient, business
تدمد: 0923-7534
DOI: 10.1016/j.annonc.2020.10.461
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d6f7e272917e31e2e10aaba952d38463
https://doi.org/10.1016/j.annonc.2020.10.461
Rights: OPEN
رقم الانضمام: edsair.doi...........d6f7e272917e31e2e10aaba952d38463
قاعدة البيانات: OpenAIRE
الوصف
تدمد:09237534
DOI:10.1016/j.annonc.2020.10.461